drugset / Trial / NCT06483048
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial tests the safety, side effects, best dose of MUC1-activated T cells in treating patients with ovarian cancer that has come back after a period of improvement (relapsed) or that remains despite treatment (resistant). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and are made in a laboratory to recognize MUC1, a protein on the surface of tumor cells that plays a key role in tumor cell growth. These MUC1-activated T cells may help the body's immune system identify and kill MUC1 expressing ovarian tumor cells.
Timeline
- Start
- 2024-09-20
- Primary completion
- 2028-09-30
- Completion
- 2028-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous MUC1-activated T-cells | Cell therapy | — | Intravenous |
| Background | Bendamustine | Small molecule | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |